Idorsia partners with Jamjoom Pharma to bring QUVIVIQ to Saudi Arabia and the Levant
Idorsia announced on 27 July 2026 an exclusive agreement with Jamjoom PharmaDealroom has a profile for this one. Try Dealroom → covering the commercialisation and distribution of QUVIVIQ (daridorexant) in Saudi Arabia and the Levant region.
QUVIVIQ is a dual orexin receptor antagonist developed by the Allschwil, Switzerland-based biopharma company for the treatment of adults with insomnia. The deal extends Idorsia's global roll-out strategy for the drug, following earlier regional partnerships in Latin America (EMS) and elsewhere, and hands commercial responsibility in the Kingdom of Saudi Arabia and the Levant markets to Jamjoom Pharma, a Jeddah-based specialty pharmaceutical group with an established Middle East and North Africa footprint.